Oorsprong van het eerstegraads netwerk van John Bondo Hansen
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 23 | |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark.
9
| Holding Company | Pharmaceuticals: Major | 9 |
Conrig Pharma ApS
 Conrig Pharma ApS Pharmaceuticals: MajorHealth Technology Conrig Pharma ApS provides drug for oral treatment of atopical disease. Its new drug (CRG-010) is use for topical treatment of itch/pruritus associated with atopical dermatitis. The company was founded by John Bondo Hansen and Mikael Sondergaard Thomsen on December 20, 2010 and is headquartered in Copenhagen, Denmark.
2
| Private Company | Pharmaceuticals: Major | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met John Bondo Hansen via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| H. LUNDBECK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
| COLOPLAST A/S | Medical Specialties | Chief Executive Officer Corporate Officer/Principal | |
Novo Nordisk Fonden
 Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark. | Investment Trusts/Mutual Funds | Chairman Chairman Director/Board Member | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Chairman Chief Executive Officer Director of Finance/CFO Chief Executive Officer | |
Ferring Pharmaceuticals A/S
 Ferring Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals A/S specializes in the development, production and marketing of pharmaceutical products. It offers products in the fields of urology, infertility, obstetrics, gynecology, gastroenterology and maternal health. The company is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chief Executive Officer President | |
DADES A/S
 DADES A/S Real Estate DevelopmentFinance DADES A/S provides real estate investment services. It owns and operates shopping centers, office buildings, and residential properties. The company was founded by Ejnar Danielsen in 1937 and is headquartered in Kongens Lyngby, Denmark. | Real Estate Development | Director/Board Member Chairman | |
Dako Denmark ApS
 Dako Denmark ApS Medical SpecialtiesHealth Technology Dako Denmark A/S designs and manufactures cancer diagnostic systems. It produces reagents, antibodies, instruments, and software solutions to make diagnoses and determine treatments for patients suffering from cancer. The firm's product areas encompass Immunohistochemistry, pharmacoDiagnostics, molecular pathology, Hematoxylin and Eosin stain, special stains, flow Cytometry, and specific proteins. The company was founded by Niels Harboe in 1966 and is headquartered in Glostrup, Denmark. | Medical Specialties | Director/Board Member | |
| Copenhagen Business School | College/University | Undergraduate Degree Graduate Degree Graduate Degree | |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Chief Executive Officer | |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Director/Board Member Sales & Marketing Corporate Officer/Principal Director/Board Member | |
| University of Aarhus | College/University | Graduate Degree Graduate Degree Doctorate Degree | |
| INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Accuro Immunology AB
 Accuro Immunology AB Pharmaceuticals: MajorHealth Technology Accuro Immunology AB develops and manufactures active immunotherapy products. The firm's products help to treat the patients suffering from problems with immune escape/evasion. The company was founded by Peter Gunnar Maurits Wolpert and Elisabeth Wolpert in 1999 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
| Technical University of Denmark | College/University | Chairman Graduate Degree | |
Glaxo Group Ltd.
 Glaxo Group Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1935, Glaxo Group Ltd. is a subsidiary of GSK Plc. The company is based in Middlesex, UK. At GSK, we unite science, technology and talent to get ahead of disease together. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
University of Linköping
 University of Linköping Other Consumer ServicesConsumer Services Linköping University Hospital provides healthcare services. | College/University | Undergraduate Degree Doctorate Degree | |
| University of Lund | College/University | Undergraduate Degree Corporate Officer/Principal | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
| International Institute for Management Development | College/University | Masters Business Admin Masters Business Admin | |
Archimedes Pharma UK Ltd.
 Archimedes Pharma UK Ltd. Medical/Nursing ServicesHealth Services Archimedes Pharma UK Ltd. involves in marketing niche pharmaceutical products. The company is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Biotechnology | Corporate Officer/Principal President Director/Board Member | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member | |
| Novo Nordisk North America, Inc. | Director of Finance/CFO Chief Tech/Sci/R&D Officer Corporate Officer/Principal | ||
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Chairman Corporate Officer/Principal | |
KDev Exploratory AB
 KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Novo Principal Investments
 Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Director of Finance/CFO Chief Executive Officer | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
COWI Holding A/S
 COWI Holding A/S Engineering & ConstructionIndustrial Services COWI Holding A/S engages in providing engineering and consulting services. The firm through its subsidiaries provides consultancy services within the fields of engineering, environmental science and economics. Its subsidiaries offer consultancy services for infrastructure such as bridges, tunnels, marine structures, airports, and mapping. The company was founded in 2010 and is headquartered in Kongens Lyngby, Denmark. | Engineering & Construction | Chairman | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Chief Tech/Sci/R&D Officer | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chairman | |
| Arts Biologics A/S | Director/Board Member | ||
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
| SYNACT PHARMA AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member Chairman | |
Beta Bionics, Inc.
 Beta Bionics, Inc. Medical SpecialtiesHealth Technology Beta Bionics, Inc. operates a medical technology company leveraging lifelong, machine-learning, artificial intelligence to develop and commercialize the autonomous bionic pancreas. The company was founded by Edward R. Damiano in October 21, 2015 and is headquartered in Boston, MA. | Medical Specialties | Director/Board Member Director/Board Member | |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Financial Conglomerates | Director of Finance/CFO Chairman Director/Board Member | |
| IO BIOTECH, INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer |
Statistieken
Internationaal
| Denemarken | 23 |
| Zweden | 16 |
| Verenigde Staten | 5 |
| Zwitserland | 4 |
| Verenigd Koninkrijk | 3 |
Sectoraal
| Health Technology | 24 |
| Finance | 9 |
| Consumer Services | 8 |
| Commercial Services | 5 |
| Health Services | 3 |
Operationeel
| Director/Board Member | 153 |
| Corporate Officer/Principal | 65 |
| Chairman | 63 |
| Independent Dir/Board Member | 31 |
| Chief Tech/Sci/R&D Officer | 26 |
Sterkste connecties
| Insiders | |
|---|---|
| Göran Albert Ando | 44 |
| Sten Scheibye | 31 |
| Jan Ulf Sigvar J. Johansson | 23 |
| Pamela Kirby | 22 |
| Emmanuelle Coutanceau | 21 |
| Peter Helt Jacobsen Haahr | 21 |
| Terje Kalland | 20 |
| Klaus Schollmeier | 17 |
| Marianne Kock | 16 |
| Carsten Boess | 15 |
| Mikael Søndergaard Thomsen | 13 |
| Jesper Høiland | 13 |
| Per Gunnar Falk | 12 |
| Henrik Gürtler | 10 |
| Adam Sinding Steensberg | 9 |
- Beurs
- Insiders
- John Bondo Hansen
- Bedrijfsconnecties
